Abstract
As expected on the basis of published research in both humans and animals, treatment with phentermine/fenfluramine lowers plasma 5-hydroxytryptamine [corrected], whereas treatment with phentermine had no significant effect. In light of these findings, future research should focus on mechanisms other than increased plasma 5-hydroxytryptamine [corrected] to explain how fenfluramine increases the risk of primary pulmonary hypertension and valvular heart disease.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Administration, Oral
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Double-Blind Method
-
Drug Therapy, Combination
-
Female
-
Fenfluramine / administration & dosage
-
Fenfluramine / pharmacokinetics
-
Fenfluramine / therapeutic use*
-
Heart Valve Diseases / blood
-
Heart Valve Diseases / etiology
-
Heart Valve Diseases / prevention & control
-
Humans
-
Hypertension, Pulmonary / blood
-
Hypertension, Pulmonary / etiology
-
Hypertension, Pulmonary / prevention & control*
-
Male
-
Middle Aged
-
Phentermine / administration & dosage
-
Phentermine / pharmacokinetics
-
Phentermine / therapeutic use*
-
Risk Factors
-
Selective Serotonin Reuptake Inhibitors / administration & dosage
-
Selective Serotonin Reuptake Inhibitors / pharmacokinetics
-
Selective Serotonin Reuptake Inhibitors / therapeutic use*
-
Serotonin / blood*
-
Sympathomimetics / administration & dosage
-
Sympathomimetics / pharmacokinetics
-
Sympathomimetics / therapeutic use*
-
Treatment Outcome
Substances
-
Serotonin Uptake Inhibitors
-
Sympathomimetics
-
Fenfluramine
-
Serotonin
-
Phentermine